Published 09:09 IST, August 14th 2020
Biological E and Janssen Pharmaceutica enter COVID-19 vaccine race
Janssen Pharmaceutica join hands with Biological E for creating and manufacturing the capacities of the Johnson & Johnson's COVID-19 vaccine candidate.
Advertisement
Biological E. Limited (BE), Hyderab-based pharmaceuticals and biologics have sealed an agreement with Janssen Pharmaceutica NV (a pharma major of Johnson & Johnson) on Thursday for creating and manufacturing capacities of Johnson & Johnson's coronavirus vaccine candidate.
Johnsons & Johnson collaborate with Biological E
Hyderab-based vaccine manufacturer issued a statement in press that stated, " vaccine candidate for Johnson & Johnson currently undergoing phase 1/2a clinical trials."
Advertisement
"We are very pleased indeed to collaborate with an organization like Johnson & Johnson. Given magnitude of COVID-19 pandemic, our ability to mount an effective response will be predicated on ability to supply vaccine globally and in significant quantities. This is best achieved through collaboration," said Mahima Datla, Managing Director of Biological E. Limited (BE).
Advertisement
"We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson's commitment to global access for its COVID-19 vaccine," Biological E. Limited (BE), Hyderab-based pharmaceuticals and biologics have sealed an agreement with Janssen Pharmaceutica NV (a pharma major of Johnson & Johnson) has sealed an agreement on Thursday for creating and manufacturing capacities of Johnson & Johnson's coronavirus vaccine candidate.
Given ever-increasing spike in coronavirus positive cases, COVID-19 vaccine is erly awaited. tally of COVID-19 cases across world is currently 21,077,917. total number of confirmed COVID-19 cases in India is 23,96,637 out of which 6,53,622 are active and 16,95,982 have alrey recovered. total number of coronavirus deaths in India are 47,033.
Advertisement
Advertisement
(With inputs from ANI)
09:09 IST, August 14th 2020